Author: Kant, Rajni; Dwivedi, Gaurav; Zaman, Kamran; Sahay, Rima R; Sapkal, Gajanan; Kaushal, Himanshu; Nyayanit, Dimpal A; Yadav, Pragya D; Deshpande, Gururaj; Singh, Rajeev; Chaowdhary, Sandeep; Gupta, Nivedita; Kumar, Sanjay; Abraham, Priya; Panda, Samiran; Bhargava, Balram
Title: Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin Cord-id: htdaalmm Document date: 2021_10_15
ID: htdaalmm
Snippet: The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
Document: The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date